Companies Dominating the Bioengineered Protein Drug Landscape
- Abbott Services
- Company Overview
- Business Strategy
- Key Product Offerings
- Financial Performance
- Key Performance Indicators
- Risk Analysis
- Recent Development
- Regional Presence
- SWOT Analysis
- Johnson & Johnson Services, Inc.
- Amgen Inc.
- Bayer AG
- Dr. Reddy’s Laboratories Ltd.
- Biocon Limited
- Eli Lilly and Company
- Sanofi S.A
- GlaxoSmithKline plc
- F. Hoffmann-La Roche Ltd
Browse key industry insights with market data tables & charts from the report:
Frequently Asked Questions (FAQ)
In the year 2025, the industry size of drone battery is assessed at USD 115.93 billion.
The bioengineered protein drug market size was valued at USD 111.3 billion in 2024 and is likely to cross USD 215.13 billion by 2037, registering more than 5.2% CAGR during the forecast period i.e., between 2025-2037. Growing prevalence of cancer and growing incidences of diabetes will boost the market growth.
North America industry is estimated to dominate majority revenue share of NA% by 2037, on the back of increasing expenditure on healthcare, both by public and private entities, along with increase in research and developmental activities and the prevalence of chronic diseases amongst individuals in the region.
The major players in the market are Abbott Services, Johnson & Johnson Services, Inc., Amgen Inc., Bayer AG, Dr. Reddy’s Laboratories Ltd., Biocon Limited, Eli Lilly and Company, Sanofi S.A, GlaxoSmithKline plc, F. Hoffmann-La Roche Ltd
